We are live on
!
Find out more
BRM
Boston Research & Management Portfolio holdings
AUM
$453M
1-Year Est. Return
20.63%
This Fund
S&P 500
This Quarter
Est. Return
+4.58%
1 Year Est. Return
+20.63%
3 Year Est. Return
+53.69%
5 Year Est. Return
+69.59%
10 Year Est. Return
+264.58%
AUM
$423M
AUM Growth
+$20.6M
(+5.1%)
Cap. Flow
+$6.95M
Cap. Flow
% of AUM
1.64%
Top 10 Holdings %
Top 10 Hldgs %
29.13%
Holding
121
New
5
Increased
39
Reduced
34
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Albemarle Corp Depositary Shares
ALB.PRA
|
+$3.73M |
| 2 |
Thermo Fisher Scientific
TMO
|
+$697K |
| 3 |
ConocoPhillips
COP
|
+$543K |
| 4 |
Merck
MRK
|
+$377K |
| 5 |
D.R. Horton
DHI
|
+$308K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$479K |
| 2 |
State Street SPDR Dow Jones Industrial Average ETF Trust
DIA
|
+$396K |
| 3 |
State Street Energy Select Sector SPDR ETF
XLE
|
+$310K |
| 4 |
Yum China
YUMC
|
+$224K |
| 5 |
Aflac
AFL
|
+$209K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 19.39% |
| 2 | Technology | 15.28% |
| 3 | Consumer Staples | 11.23% |
| 4 | Healthcare | 10.96% |
| 5 | Financials | 10.47% |
Similar funds
BFT
BAMG
CI
ACM
IP
FDS
BWA
WC
Boston Research & Management's Q2 2025 Portfolio in Review
As of Q2 2025, Boston Research & Management held 121 positions worth $423M, up 5.1% from $403M the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Boston Research & Management's Q2 2025 filing shows 5 new, 39 increased, 34 reduced and 4 closed positions. Its largest new stake was Albemarle Corp Depositary Shares: 121,960 shares worth $3.91M. The largest sale was iShares Core S&P 500 ETF, an estimated $479K.
By sector, the portfolio is most concentrated in Miscellaneous at 19% of assets, up from 18% a quarter earlier, followed by Technology and Consumer Staples.
- Boston Research & Management's largest Q2 2025 buy was Albemarle Corp Depositary Shares: 121,960 shares worth $3.91M.
- Boston Research & Management added most to Thermo Fisher Scientific in Q2 2025, an estimated $697K increase.
- Boston Research & Management's biggest Q2 2025 reduction was iShares Core S&P 500 ETF, cutting an estimated $479K.
- Boston Research & Management fully exited Yum China in Q2 2025, selling an estimated $224K.
- Boston Research & Management's ten largest holdings make up 29% of its $423M portfolio in Q2 2025.
- Boston Research & Management opened 5 new positions and closed 4 in Q2 2025.
- Boston Research & Management's portfolio value rose 5.1% quarter-over-quarter to $423M.
Based on Boston Research & Management's 13F filing for Q2 2025, filed 12 Aug 2025.